NALTREXONE, AN OPIATE ANTAGONIST, FAILS TO MODIFY MOTOR SYMPTOMS IN PATIENTS WITH PARKINSONS-DISEASE

被引：68

作者：

RASCOL, O

FABRE, N

BLIN, O

POULIK, J

SABATINI, U

SENARD, JM

ANE, M

MONTASTRUC, JL

RASCOL, A

机构：

[1] UNIV HOSP TOULOUSE,INSERM,U317,DEPT CLIN PHARMACOL,TOULOUSE,FRANCE

[2] UNIV HOSP TOULOUSE,INSERM,U230,DEPT NEUROL,TOULOUSE,FRANCE

[3] UNIV HOSP TOULOUSE,DEPT PHARM,TOULOUSE,FRANCE

[4] UNIV HOSP MARSEILLE,DEPT CLIN PHARMACOL,MARSEILLE,FRANCE

来源：

MOVEMENT DISORDERS | 1994年 / 9卷 / 04期

关键词：

NALTREXONE; PARKINSONS DISEASE; MOTOR SYMPTOMS;

D O I：

10.1002/mds.870090410

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.

引用

页码：437 / 440

页数：4

共 31 条

[1] PEPTIDES AND PARKINSONS-DISEASE [J].